PRIME Study

The PRIME Study is Neuralink's first trial in humans, a test of whether a coin-sized brain implant can let a person with severe paralysis control a computer or a phone by thought alone. PRIME stands for Precise Robotically Implanted Brain-Computer Interface. Its first participant, implanted on January 28, 2024, learned to move a cursor just by intending to move it, and the very next day Elon announced the product had a name: Telepathy.

What is the PRIME Study?

PRIME is an early feasibility study registered with the United States National Library of Medicine as NCT06429735. It tests two pieces of hardware together: the N1, a coin-sized implant that reads brain activity, and R1, the surgical robot that places it. A brain-computer interface (BCI) is a system that turns brain signals directly into commands for a device. The N1 carries 1,024 electrodes spread across 64 threads, each thinner than a human hair, all listening to the motor cortex, which is the part of the brain that forms the intention to move.

Why the PRIME Study Exists

The trial is built for people with quadriplegia, meaning paralysis in all four limbs, caused by a neck spinal cord injury or by amyotrophic lateral sclerosis (ALS, a progressive disease that destroys the nerves that control muscle). Participants must be at least one year past their injury with no improvement, and at least 22 years old. For these people, even a single mouse click is out of reach. The United States Food and Drug Administration (FDA) granted the Investigational Device Exemption (IDE) that legally permits the trial in May 2023, and recruitment opened that September. The goal is simple to state: read the intention to move from the brain, and hand it back as control on a screen.

How it Works

The R1 robot places the threads with a precision no human hand can match. The N1 then reads the firing of individual brain cells and turns the user's intended movement into cursor motion. Speed is measured in bits per second (BPS), a unit that captures how much thought-to-action information flows each second. During his first research session, the first participant set a world record for BCI cursor control at 4.6 BPS, then later reached 8.0. A different participant went on to top 10. Typing has reached up to 40 words per minute.

The Economics of the PRIME Study

Nothing is for sale. The N1 implant, the R1 robot, and the companion app are all still experimental, and participants are paid only for study-related costs such as travel. What stands in for revenue is the surgical record. One implant in the first half of 2024 grew to thirteen in the second half of 2025, and stacking those half-years gives a running total that climbs steeply. As the robot takes on more of the work, the cost and effort of each surgery can fall, which is how a future product category would eventually pay for itself.

Current Status of PRIME Study

By the two-year mark on January 28, 2026, Neuralink reported 21 enrolled participants, whom it calls Neuralnauts, and a stated record of zero serious device-related adverse events across 20 surgeries. One participant logged as much as 17 hours of use in a single day. The program now spans four countries: the United States, Canada, the United Kingdom, and the United Arab Emirates. Twenty brain surgeries in twenty-four months with no serious device failures is the quiet result that tells you where the trial stands.

What Comes Next

PRIME's 18-month main phase is followed by a 5-year safety follow-up, which puts the full study near six years. It has already branched out. CONVOY tests N1 control of a helper robotic arm, and VOICE aims to restore speech, with a stated conversational goal of 140 words per minute. The international versions (CAN-PRIME, UAE-PRIME, and GB-PRIME) open access well beyond the original American sites. Each spinoff is a fresh test of what a single implant can read, and each one adds follow-up care and software around a small but growing group of users.

The Bottom Line

PRIME has shown, with a real surgical record rather than a promise, that a wireless, high-channel implant can hand digital control back to people who had lost it. The numbers are still measured in dozens, not millions. But the direction, meaning faster decoding, more sites, and more uses, is the part worth watching as the trial moves toward its end. This is the greatest engineer of our time doing what he does best, turning a bold idea into a working machine and then improving it in public.

Related

Keep reading: R1 Surgical Robot, Telepathy. Zoom out to the Neuralink overview, or open the Glossary.